New transplant approach aims to beat back aggressive leukemia in young adults
NCT ID NCT07372885
First seen Jan 29, 2026 · Last updated Apr 28, 2026 · Updated 9 times
Summary
This trial tests a new way to do a stem cell transplant for young adults (ages 16-55) with very aggressive acute myeloid leukemia (AML) that hasn't responded to chemo or has high-risk gene changes. Instead of a standard transplant, patients receive umbilical cord blood plus extra infusions of white blood cells called granulocytes. The goal is to see if this approach is safe and works better than a regular transplant to prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kings College Hospital NHS Trust
London, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact Email: •••••@•••••
Contact
-
The Royal Marsden Hospital NHS Foundation Trust
London, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.